Superluminal Medicines raised an oversubscribed $60 million Series B to advance its AI-powered GPCR platform and initiate a Phase I trial by year-end. The company’s lead asset is a selective, biased melanocortin-4 receptor (MC4R) agonist aimed at rare genetic obesity and hypothalamic obesity, with investors including BVF Partners and participation from Deep Track Capital, Perceptive Advisors, RA Capital, Insight, NVIDIA, and Eli Lilly.